Cardiff Oncology, Inc. (CRDF) 2019年年度报告「NASDAQ」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549Form 10-K(Mark One)xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2019oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934

2、For the Transition Period from to Commission File Number:001-35558TROVAGENE,INC.(Exact name of registrant as specified in its charter)Delaware 27-2004382(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)11055 Flintkote Avenue,San Diego,California 92121(

3、Address of principal executive offices)(Zip Code)(858)952-7570(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each class Name of each exchange on which registeredCommon Stock,$0.0001 par value The NASDAQ Capital MarketSecurities re

4、gistered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes o No xIndicate by check if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes o

5、 No xIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such

6、filingrequirements for the past 90 days.Yes x No oIndicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data Filerequired to be submitted and posted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)durin